Cargando…
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880907/ https://www.ncbi.nlm.nih.gov/pubmed/35224552 http://dx.doi.org/10.1002/bco2.125 |
| _version_ | 1784659347212599296 |
|---|---|
| author | Adib, Elio El‐Zarif, Talal Jain, Rohit K. Skelton, William P. Freeman, Dory Curran, Catherine Akl, Elie W. Nassar, Amin H. Ravi, Praful Mantia, Charlene Kwiatkowski, David J. Choueiri, Toni K. Sonpavde, Guru P. |
| author_facet | Adib, Elio El‐Zarif, Talal Jain, Rohit K. Skelton, William P. Freeman, Dory Curran, Catherine Akl, Elie W. Nassar, Amin H. Ravi, Praful Mantia, Charlene Kwiatkowski, David J. Choueiri, Toni K. Sonpavde, Guru P. |
| author_sort | Adib, Elio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8880907 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88809072022-03-01 FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma Adib, Elio El‐Zarif, Talal Jain, Rohit K. Skelton, William P. Freeman, Dory Curran, Catherine Akl, Elie W. Nassar, Amin H. Ravi, Praful Mantia, Charlene Kwiatkowski, David J. Choueiri, Toni K. Sonpavde, Guru P. BJUI Compass RESEARCH COMMUNICATION John Wiley and Sons Inc. 2021-11-10 /pmc/articles/PMC8880907/ /pubmed/35224552 http://dx.doi.org/10.1002/bco2.125 Text en © 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | RESEARCH COMMUNICATION Adib, Elio El‐Zarif, Talal Jain, Rohit K. Skelton, William P. Freeman, Dory Curran, Catherine Akl, Elie W. Nassar, Amin H. Ravi, Praful Mantia, Charlene Kwiatkowski, David J. Choueiri, Toni K. Sonpavde, Guru P. FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma |
| title |
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma |
| title_full |
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma |
| title_fullStr |
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma |
| title_full_unstemmed |
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma |
| title_short |
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma |
| title_sort | fgfr2/3 genomic alterations and response to enfortumab vedotin in metastatic urothelial carcinoma |
| topic | RESEARCH COMMUNICATION |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880907/ https://www.ncbi.nlm.nih.gov/pubmed/35224552 http://dx.doi.org/10.1002/bco2.125 |
| work_keys_str_mv | AT adibelio fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT elzariftalal fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT jainrohitk fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT skeltonwilliamp fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT freemandory fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT currancatherine fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT akleliew fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT nassaraminh fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT ravipraful fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT mantiacharlene fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT kwiatkowskidavidj fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT choueiritonik fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma AT sonpavdegurup fgfr23genomicalterationsandresponsetoenfortumabvedotininmetastaticurothelialcarcinoma |